Concord Medical Services
Concord Medical Services' revenue rose 19.9% to CN¥460 million in fiscal 2025. Its operating margin was −56.8%, up from −138.6% a year earlier. Free cash flow was −CN¥258 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
What Concord Medical Services does
Concord Medical Services runs cancer hospitals and clinics in China and supplies cancer-treatment equipment to other hospitals there. At the end of 2025 it had four hospitals and clinics of its own: a full cancer hospital in Guangzhou, two clinics and an imaging center in Shanghai. They offer screening, scans, radiation therapy, chemotherapy, surgery and care after treatment. The Guangzhou hospital opened a proton therapy center, a precise form of radiation treatment, in December 2024.
The company reports two businesses. The hospital business, its own hospitals and clinics, brought in RMB373.9 million in 2025. The network business leases radiation and imaging machines, such as linear accelerators and PET-CT scanners, to partner hospitals, runs the non-medical side of these centers and takes an agreed share of each center's revenue; it brought in RMB86.6 million, down as the company stops renewing expired leases. At the end of 2025 it served eight such centers in six hospitals. Total revenue was RMB460.5 million.
The company is building a second cancer hospital in Shanghai, with 400 beds, which it expects to open in 2027, and runs an online hospital for cancer patients. It works with the University of Texas MD Anderson Cancer Center, which advises its hospitals under a consulting agreement. It has made losses, and its 20-F says there is substantial doubt about its ability to continue as a going concern.
Its biggest risks, as it describes them
- Building and opening new cancer hospitals and proton centers takes a lot of money, and new hospitals may take a long time to make a profit.
- It has made losses, burned cash and carries large debts, which raise doubt about its ability to keep operating.
- Much of its revenue comes from a few partner hospitals and from Shanghai and Guangzhou, so trouble in one can hurt it badly.
- It may not hire and keep enough qualified doctors and other medical staff.
- It works in a heavily regulated industry in China, where some prices are set by public insurance rules.
Income statement
Concord Medical Services lost money in fiscal 2025: a net loss of CN¥93 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 157 | 158 | 58 | 351 | 298 |
| Debt incl. finance leases | 2,478 | 2,984 | 3,036 | 3,726 | 3,447 |
| Net debt (negative means net cash) | 2,320 | 2,826 | 2,978 | 3,376 | 3,149 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −6.2x | −4.4x | −2.8x | −2.8x | −1.7x |
| Current ratio | 0.7x | 0.7x | 0.3x | 0.5x | 0.5x |
| Quick ratio | 0.7x | 0.6x | 0.3x | 0.5x | 0.5x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 2 of 9 | 6 of 9 |
| Rule of 40 | −58.6% | −171.4% | −36.1% |
| Altman Z'' | −3.72 | −3.43 | −3.09 |
| Accruals ratio | −0.3% | 1.4% | 1.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 5 of 9 | 2 of 9 | 6 of 9 |
Compare
Put Concord Medical Services side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Concord Medical Services | FY25 | 19.9% | −56.8% | −56.1% | −4.1% | — | 6 | |
| GeneDx | FY25 | 40.0% | −3.1% | 3.3% | −5.3% | — | 6 | Compare |
| Starling Oncology | FY25 | 27.8% | −7.2% | −5.5% | −75.7% | — | 3 | Compare |
| Veracyte | FY25 | 16.0% | 11.2% | 24.5% | 6.1% | −4.6x | 6 | Compare |
| PomDoctor | FY25 | 16.7% | −29.7% | −37.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 455 | 331 | 191 | 198 | 223 | 486 | 472 | 537 | 384 | 460 |
| Revenue growth | −26.2% | −27.3% | −42.3% | 3.9% | 12.4% | 117.8% | −2.8% | 13.8% | −28.6% | 19.9% |
| Gross profit | 168 | 98 | 20 | −16 | 13 | −57 | −152 | −77 | −79 | 26 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | −169 | −212 | −299 | −437 | −316 | −458 | −525 | −463 | −532 | −262 |
| Net income | −262 | −284 | −235 | −307 | −310 | −271 | −490 | −298 | −308 | −93 |
| Diluted EPS (CNY) | −2.00 | −2.19 | −2.76 | −4.24 | −5.11 | −6.26 | −3.74 | −2.27 | −2.35 | −0.71 |
| Diluted shares (millions) | 131 | 130 | 130 | 130 | 131 | 131 | 131 | 131 | 131 | 131 |
| Cash flow | ||||||||||
| Cash from operations | −78 | 27 | −39 | −195 | −230 | −359 | −217 | −276 | −398 | −202 |
| Capital expenditure | 79 | 91 | 166 | 233 | 168 | 279 | 223 | 113 | 151 | 56 |
| Free cash flow | −157 | −65 | −204 | −428 | −398 | −638 | −440 | −389 | −549 | −258 |
| Dividends paid | 286 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 26 | 0 | 529 | 421 | 8 | 2 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 12 | 11 | 21 | 21 | 15 | −6 | 0 | — | — |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | — | 98 | 455 | 74 | 334 | 157 | 158 | 58 | 351 | 298 |
| Debt incl. finance leases | 861 | 761 | 938 | 1,620 | 2,117 | 2,478 | 2,984 | 3,036 | 3,726 | 3,447 |
| Total assets | 3,229 | 3,465 | 4,585 | 4,297 | 5,334 | 6,230 | 6,005 | 6,054 | 6,726 | 6,547 |
| Total liabilities | 1,997 | 2,450 | 2,312 | 2,408 | 2,934 | 3,486 | 3,989 | 4,307 | 5,109 | 4,697 |
| Shareholders' equity | 1,166 | 934 | 437 | −123 | −663 | −1,370 | −1,864 | −2,122 | −2,280 | −2,103 |
| Margins and ratios | ||||||||||
| Gross margin | 37.0% | 29.6% | 10.3% | −8.0% | 5.9% | −11.7% | −32.3% | −14.3% | −20.6% | 5.6% |
| Operating margin | −37.1% | −64.0% | −156.8% | −220.4% | −141.7% | −94.4% | −111.2% | −86.2% | −138.6% | −56.8% |
| Net margin | −57.5% | −85.9% | −123.0% | −154.8% | −139.0% | −55.9% | −103.7% | −55.4% | −80.3% | −20.1% |
| Free cash flow margin | −34.5% | −19.5% | −107.0% | −215.8% | −178.4% | −131.4% | −93.1% | −72.5% | −142.9% | −56.1% |
| Rule of 40 (growth + FCF margin) | −60.7% | −46.8% | −149.3% | −211.9% | −165.9% | −13.7% | −95.9% | −58.6% | −171.4% | −36.1% |
| Return on capital | — | — | −18.7% | −34.1% | −22.6% | −34.5% | −13.3% | −7.7% | −8.7% | −4.1% |
| Return on equity | −20.5% | −27.1% | −34.2% | — | — | — | — | — | — | — |
| Return on assets | −7.7% | −8.5% | −5.8% | −6.9% | −6.4% | −4.7% | −8.0% | −4.9% | −4.8% | −1.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |